Industry news round-up: updates from June 2023
In this latest instalment of our regular monthly column, we summarize a selection of key industry developments that have taken place over the past month, including developments with the Inflation Reduction Act.
From Industry
Verana Health steps into clinical trial site selection with launch of real-world evidence tool VeraSite
VeraSite can help clinical trial sponsors and contract research organizations streamline ophthalmology clinical trials using real-world patient data to identify potential clinical trial sites.
Holmusk and Streamline Healthcare Solutions partner to bring behavioral health predictive real-world data analytics tool to US
The partnership between Holmusk and Streamline Healthcare Solutions will see the introduction of Holmusk’s MaST software platform into the US market through deployment of the tool by Mental Health Partners in Colorado.
Endo International announces largest real-world data registry in Dupuytren’s contracture underway with first patient enrolled
The GRASP-DC registry will eventually contain the largest and most comprehensive collection of RWD on treatment outcomes for up to 1000 people with Dupuytren’s contracture.
Flatiron Health steps into the UK through new real-world oncology data partnership with Leeds Teaching Hospitals NHS Trust
Signaling a new phase in its global growth strategy, Flatiron announces an alliance with major UK hospital, Leeds Teaching Hospitals NHS Trust, to translate real-world oncology data of people with cancer into research-ready datasets for improving cancer research and care.
OMNY Health and Datavant partner to improve clinical research and drug development by accelerating real-world data delivery
OMNY Health and Datavant will synergistically combine their respective vast healthcare data ecosystem and privacy-centric data connectivity tools to advance the large-scale harnessing of RWD.
Mitsubishi Tanabe Pharma America announces collaboration with ALS/MND Natural History Study Consortium to advance real-world data in amyotrophic lateral sclerosis
Mitsubishi Tanabe Pharma America will use RWD collected by the ALS/MND Natural History Study Consortium to help the company learn more about the demographics, natural history and treatment of people living with amyotrophic lateral sclerosis.
IDERHA consortium formed to tackle access, integration and use of digital healthcare data to advance research and care in lung cancer
Academic, clinical, medtech, pharmaceutical, IT, patient advocacy organizations and public authorities will work together within the IDERHA consortium to advance digital healthcare data in lung cancer that will ultimately improve clinical decision making and enhance patient access to health innovations.
NESTcc issues request for partners in generating real-world data to support improved evidence for medical devices
The National Evaluation System for health Technology Coordinating Center is inviting new partners to catalyse and enhance real-world data and evidence generation for medical devices through the Request for Information 23-001 entitled ‘Medical Device Real-World Evidence Marketplace’.
BC Platforms extends Global Data Partner network through collaboration with leading cardiology center in Brazil
By working one of Brazil’s leading cardiology centers, Hospital do Coração, BC Platforms will capture RWD from people affected by cardiovascular diseases within its Global Data Partner network, BCRQUEST.COM, to help advance understanding of this area.
Inflation Reduction Act
Impact of the Inflation Reduction Act on drug development and patients: an interview with Jason Spangler, Innovation and Value Initiative
In this interview we hear from Jason Spangler, CEO of the Innovation and Value Initiative to understand the potential effect this landmark legislation may have on drug development and patients.
Impact of the Inflation Reduction Act on US health care: an interview with Corey Ford and Kimberly Westrich, Xcenda
We speak with Corey Ford and Kimberly Westrich of AmerisourceBergen’s Xcenda to explore the law’s provisions and its wider implications for drug development, health care and health policy.
The Inflation Reduction Act in numbers: impact on the development of small molecule medicines
Further research into the effect of the Inflation Reduction Act on US health care, this time by Partnership for Health Analytic Research (PHAR), has found there could be a significant impact on post-approval research and development of small molecule medicines.
The Inflation Reduction Act in numbers: estimating the impact of implementing Medicare drug pricing policies on the US healthcare ecosystem
Research firm Vital Transformation has recently released two reports modeling the impact of emerging government-mandated drug pricing policies in Medicare stemming from the Inflation Reduction Act on medical innovation and jobs.
PhRMA joins legal battle against Medicare drug pricing provisions in the Inflation Reduction Act
PhRMA, along with National Infusion Center Association and the Global Colon Cancer Association, claim the drug pricing provisions in the Inflation Reduction Act are ‘unconstitutional’.
Merck files lawsuit against US government over Medicare drug price negotiation program – will others follow?
Merck became the first company to file a lawsuit against the US government over the drug price negotiation program required under the Inflation Reduction Act.
